Track topics on Twitter Track topics that are important to you
MorphoSys AG / Key word(s): Miscellaneous
Ad hoc release according to article 17 MAR
Ad hoc: MorphoSys Announces that According to a Presentation Title at an Upcoming Conference, Guselkumab Demonstrates Superior Long-Term Responses to Secukinumab at Week 48 in the Treatment of Moderate to Severe Psoriasis
MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX TecDAX; NASDAQ: MOR) announced today that according to the title of a presentation to be held next Wednesday afternoon CET (December 12, 2018) at the upcoming Inflammatory Skin Disease Summit (ISDS) conference in Vienna, Austria, guselkumab [Tremfya(R)] demonstrates superior long-term responses to secukinumab [Cosentyx(R)] at Week 48 in the treatment of moderate to severe psoriasis, as results from the ECLIPSE trial. The presentation title has been published online at the website of the ISDS conference (http://www.isds2018.org/scientific-program).
MorphoSys expects that this announcement relates to an upcoming presentation of clinical data from the so called "ECLIPSE" clinical study. The ECLIPSE trial has been conducted by MorphoSys' licensee Janssen, comparing the efficacy of guselkumab [Tremfya(R)] to secukinumab [Cosentyx(R)], for the treatment of adults with moderate to severe plaque psoriasis, at week 48.
MorphoSys notes that except for the presentation title no further information is yet available and that no detailed study results are yet available, ahead of the presentation at the conference expected to be held on December 12, 2018.
Tremfya(R) is a human anti-IL-23 monoclonal antibody developed by Janssen that was generated utilizing MorphoSys' proprietary HuCAL antibody technology. MorphoSys is eligible to certain milestone payments and receives royalties on net sales of Tremfya(R).
Tremfya(R) has been approved in the U.S., Canada, the European Union, and several other countries for the treatment of plaque psoriasis and in Japan for the treatment of various forms of psoriasis, psoriatic arthritis, and palmoplantar pustulosis. Guselkumab [Tremfya(R)] is currently being investigated in clinical studies in several indications, including the phase 3 ECLIPSE trial evaluating the efficacy of guselkumab [Tremfya(R)] compared with secukinumab [Cosentyx(R)] for the treatment of adults with moderate to severe psoriasis.
END OF AD HOC RELEASE
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group. Tremfya(R) is a trademark of Janssen Biotech, Inc. Cosentyx(R) is a trademark of Novartis AG.
For more information, please contact:
Tel: +49 (0) 89 / 899 27-404
|Phone:||+49 (0)89 899 27-0|
|Fax:||+49 (0)89 899 27-222|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|End of Announcement||DGAP News Service|
Original Article: Ad hoc: MorphoSys Announces that According to a Presentation Title at an Upcoming Conference, Guselkumab Demonstrates Superior Long-Term Responses to Secukinumab at Week 48 in the Treatment of Moderate to Severe PsoriasisNEXT ARTICLE
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...
Biocon Launches ALZUMAb™ - a ‘First in Class’ Novel Biologic Treatment for Psoriasis Patients in India • ALZUMAb™-World's first novel anti-CD6 antibody developed by Biocon to address a large unmet need for th...